CME
Case 4: In Patients Ineligible for Platinum-Based Chemotherapy, What Is the Ideal IO-Based Approach?
Host: Charu Aggarwal, MD, MPH
Host: Joshua E. Reuss, MD
The role of immunotherapy (IO) in the management of advanced and metastatic NSCLC continues to evolve, with several new frontline IO-based therapy regimens receiving FDA approval in the